LUND, SWEDEN -- (MARKET WIRE) -- 09/18/2006 -- Lund, Sweden, 18 September 2006. Active Biotech (Stockholm: ACTI.ST) management is scheduled to present at the UBS Global Life Sciences Conference on Wednesday, September 27 at the Grand Hyatt Hotel in New York City, US. During the presentation, management will provide an update on the Active Biotech development programs.

The presentation will include laquinimod, an oral immunmodulatory Multiple Sclerosis drug which is licensed to Teva Pharmaceutical Industries Ltd and recently successfully concluded a Phase IIb study; ANYARA, Active Biotech's novel concept for the treatment of lung and renal cancer; and other key projects in clinical development; TASQ, for prostate cancer; 57-57, for Lupus (SLE) and RhuDex® (licensed to Avidex Ltd.) for Rheumatoid Arthritis. The presentation will also cover the I-3D project, which Active Biotech is co-developing with Chelsea Therapeutics.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site.

A replay will be available approximately three hours following the presentation and can be accessed via the company's web site.

To access the live and replay presentations please go to - www.activebiotech.com.

The presentation will take place on September 27, at 9:00 am US Eastern Time / 15:00 Central European Time.

About Active Biotech

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects comprise the three orally administered compounds in clinical development, TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA as well as the I-3D project in pre-clinical co-development with Chelsea Therapeutics.

Contacts:

Active Biotech AB                        U.S. Investors
Cecilia Hofvander                        Kathy Price
P.O. Box 724, SE-220 07 Lund, Sweden     The Global Consulting Group
Tel: +46 (0)46-19 20 00                  Tel: +1-(646) 284-9430
Fax: +46 (0)46-19 20 50                  Email: kprice@hfgcg.com

                                         Emmanuelle Ferrer
                                         The Global Consulting Group
                                         +1-(646) 284-9421
                                         eferrer@hfgcg.com

Copyright © Hugin ASA 2006. All rights reserved.